37404-23-2

Basic information

• Product Name: Propanoic acid, 2-(4-iodophenoxy)-2-methyl-
• CAS NO: 37404-23-2
• Molecular Formula: C10H11IO3
• Molecular Weight: 306.1
• Mol File: 37404-23-2.mol

Chemical Properties

• CAS DataBase Reference: Propanoic acid, 2-(4-iodophenoxy)-2-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Propanoic acid, 2-(4-iodophenoxy)-2-methyl-(37404-23-2)
• EPA Substance Registry System: Propanoic acid, 2-(4-iodophenoxy)-2-methyl-(37404-23-2)

Safety Data

• Hazardous Substances Data: 37404-23-2(Hazardous Substances Data)

Upstream product

• 540-38-5 p-Iodophenol 
• 37404-22-1 ethyl 2-(4-iodophenoxy)-2-methylpropanoate 
• 67-66-3 chloroform 
• 67-64-1 acetone 

Downstream Products

• 29941-94-4 2-(4-benzoylphenoxy)-2-methylpropanoic acid 
• 42017-89-0 fenofibric acid 
• 17431-97-9 2-(4-nitrophenoxy)-2-methylpropanoic acid 
• 124188-27-8 2-(4-iodo-2-nitrophenoxy)-2-methylpropanoic acid 
• 37404-22-1 ethyl 2-(4-iodophenoxy)-2-methylpropanoate 

Relevant articles and documents

Water-based biphasic media for exothermic reactions: Green chemistry strategy for the large scale preparation of clofibric acid and analogues

A water-based biphasic reaction process has been developed for conducting exothermic reactions without organic solvents. This procedure is rapid, simple, and suitable for small scale synthesis as well as larger (multi-molar) scale reactions. The preparation of several hundred grams of clofibric acid and analogues by this eco-friendly and energy-efficient procedure is described. Smaller amounts of these compounds were prepared by the friction-activated 'Grindstone Chemistry' method described previously.

TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE

Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

WNT PATHWAY MODULATORS

The invention provides a compound of structure Ar1-Ar2-X-C(R1R2)-C(=O)-N(R3)-Ar3-Ar4 for modulating WNT activity. In this structure, Ar1, Ar2, Ar3 and Ar4 are, independently, optionally substituted aryl or heteroaryl groups; R1 and R3 are, independently, H or optionally substituted alkyl groups; R2 is H or an optionally substituted alkyl group or an alkylene group which, together with the carbon atom to which it is attached and X, forms a non-aromatic ring or an alkylene group which, together with the carbon atom to which it is attached and X and two adjacent atoms of Ar2, forms a non-aromatic ring; X is O, CR4R5, N or NR4, wherein if X is N, it is bonded to R2; R4 is H, optionally substituted alkyl or an alkylene chain, optionally containing a heteroatom and/or a carbonyl group, which, together with the C or N to which it is attached and two adjacent atoms of Ar2, forms a non-aromatic ring; R5 is H, NH2 or an optionally substituted alkyl group.